Literature DB >> 16335858

Healing of oesophagitis.

L Rodrigo1.   

Abstract

The reflux oesophagitis treatment aims to achieve a rapid and sustained symptom relief and a high percentage of lesion healing, apart from preventing the relapses and complications of the disease. For that purpose it is essential to maintain the oesophagic pH above 4 for as long as possible during the day and the night. All these objectives are achieved with the use of the proton pump inhibitors (PPI), which constitute the most effective drug group--being superior to the rest of the antisecretory drugs, such as anti-H2, which are no longer in use in this treatment. In moderate grades (grades A and B), all the PPIs used at their usual dosages show a similar treatment efficacy within 8 weeks. In severe cases (grades C and D), as well as those complicated with digestive haemorrhagia or Barrett's oesophagus, esomeprazole shows a higher treatment efficacy than the rest of the PPIs and is therefore the drug of choice. Furthermore, esomeprazole, an active isomer of omeprazole, shows other properties such as a higher rate of action, a lower interindividual variation and a more prolonged mode of action, which all translate into additional advantages in comparison with the rest of the PPIs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16335858     DOI: 10.2165/00003495-200565001-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  20 in total

1.  Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.

Authors:  E C Klinkenberg-Knol; F Nelis; J Dent; P Snel; B Mitchell; P Prichard; D Lloyd; N Havu; M H Frame; J Romàn; A Walan
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

2.  Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.

Authors:  S J Edwards; T Lind; L Lundell
Journal:  Aliment Pharmacol Ther       Date:  2001-11       Impact factor: 8.171

3.  The pattern of esophageal acid exposure in gastroesophageal reflux disease influences the severity of the disease.

Authors:  G M Campos; J H Peters; T R DeMeester; S Oberg; P F Crookes; R J Mason
Journal:  Arch Surg       Date:  1999-08

4.  Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis.

Authors:  V K Sharma; G I Leontiadis; C W Howden
Journal:  Aliment Pharmacol Ther       Date:  2001-02       Impact factor: 8.171

5.  Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.

Authors:  Donald O Castell; Peter J Kahrilas; Joel E Richter; Nimish B Vakil; David A Johnson; Seth Zuckerman; Wendy Skammer; Jeffrey G Levine
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

6.  Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.

Authors:  P J Kahrilas; G W Falk; D A Johnson; C Schmitt; D W Collins; J Whipple; D D'Amico; B Hamelin; B Joelsson
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

7.  Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group.

Authors:  C J Mulder; W Dekker; M Gerretsen
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-11       Impact factor: 2.566

8.  Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.

Authors:  J E Richter; P J Kahrilas; J Johanson; P Maton; J R Breiter; C Hwang; V Marino; B Hamelin; J G Levine
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

9.  Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.

Authors:  Philip Miner; Philip O Katz; Yusong Chen; Mark Sostek
Journal:  Am J Gastroenterol       Date:  2003-12       Impact factor: 10.864

Review 10.  Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease.

Authors:  N Vakil; M B Fennerty
Journal:  Aliment Pharmacol Ther       Date:  2003-09-15       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.